{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:06:12Z","timestamp":1793045172975,"version":"4.5.0"},"reference-count":24,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,2,10]],"date-time":"2009-02-10T00:00:00Z","timestamp":1234224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>Quercetin, one of the most abundant natural flavonoids, has been reported to modulate the activity of several drug\u2010metabolising enzymes. The aim of the present study was to investigate the effects of quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, <jats:italic>N<\/jats:italic>\u2010acetyltransferase (NAT2) and xanthine oxidase (XO) activity in healthy volunteers using caffeine as a probe drug.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Twelve unrelated, healthy volunteers were recruited to the study. There were two phases to the study; in the first phase, each subject was given a single oral dose of caffeine (one 100\u00a0mg capsule) with 150\u00a0mL water; in the second phase, each subject was give a 500\u00a0mg quercetin capsule once daily for 13 continuous days and was coadministered a 100\u00a0mg caffeine capsule on the 13th day. Urinary caffeine metabolite ratios were used as indicators of the activity of CYP1A2, CYP2A6, NAT2 and XO. The pharmacokinetics of caffeine and its metabolites were determined by HPLC.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In the quercetin\u2010treated group, CYP1A2 activity was decreased by 10.4% (95% confidence interval (CI), 1.1\u201329.8%; <jats:italic>P<\/jats:italic>\u00a0= 0.039), whereas increases were observed in CYP2A6 (by 25.3%; 95% CI, 6.2\u201334.5%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.002), NAT2 (by 88.7%; 95% CI, 7.1\u2013160.2%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.010) and XO activity (by 15.0%; 95% CI, 1.6\u201321.6%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.007). Plasma C<jats:sub>max<\/jats:sub> and the AUC<jats:sub>(0\u201324\u00a0h)<\/jats:sub> of 1,7\u2010dimethylxanthine were decreased by 17.2% (95% CI, 6.4\u201328.0%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.024) and 16.2% (95% CI, 3.9\u201328.5%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.032), respectively. The urinary excretion of 1,7\u2010dimethylxanthine and 1\u2010methylxanthine was significantly decreased by 32.4% (95% CI, 2.5\u201362.1%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.036) and 156.1% (95% CI, 53.3\u2013258.9%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.004), respectively. The urinary excretion of 1,7\u2010dimethylurate and 1\u2010methylurate was increased by 82.9% (95% CI, 56.0\u2013165.4%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.030) and 97.8% (95% CI, 12.1\u2013183.5%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.029), respectively. No changes were observed in the urinary excretion of caffeine and 5\u2010acetylamino\u20106\u2010formylamino\u20103\u2010methyluracil between the two study phases.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The results of the present study indicate that quercetin inhibits CYP1A2 function, but enhances CYP2A6, NAT2 and XO activity. Simultaneously, some pharmacokinetic parameters relating to 1,7\u2010dimethylxanthine were affected by quercetin. Thus, we conclude that quercetin affects CYP1A2, CYP2A6, NAT2 and XO activity <jats:italic>in vivo<\/jats:italic>.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p>","DOI":"10.1111\/j.1440-1681.2009.05158.x","type":"journal-article","created":{"date-parts":[[2009,2,10]],"date-time":"2009-02-10T15:43:23Z","timestamp":1234280603000},"page":"828-833","source":"Crossref","is-referenced-by-count":67,"title":["SIMULTANEOUS ACTION OF THE FLAVONOID QUERCETIN ON CYTOCHROME P450 (CYP) 1A2, CYP2A6, <i>N<\/i>\u2010ACETYLTRANSFERASE AND XANTHINE OXIDASE ACTIVITY IN HEALTHY VOLUNTEERS"],"prefix":"10.1111","volume":"36","author":[{"given":"Yao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong\u2010Sheng","family":"Ou\u2010Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi\u2010Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang\u2010Hua","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan\u2010Fei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong\u2010Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,7,28]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/68.1.60"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj3400715"},{"key":"e_1_2_6_4_2","first-page":"711","article-title":"The quantitation of metabolites of quercetin flavonols in human urine","volume":"5","author":"Gross M","year":"1996","journal-title":"Cancer Epidemiol. Biomarkers Prev"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0272-0590(92)90181-G"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.4.9.1908"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/72.5.1150"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2006.08.002"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1207\/S15327914NC441_13"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2007.02.020"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(98)00016-4"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.736"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1987.126"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2003.08.002"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2004.12.004"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2006.01.028"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(02)02235-X"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2005.pto_98.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1383-5718(01)00267-4"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(01)00656-2"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1983.80"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199206000-00003"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)00325-X"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(01)00546-5"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1733-1738.2005"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1681.2009.05158.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1681.2009.05158.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T02:56:59Z","timestamp":1696906619000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1681.2009.05158.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,28]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1111\/j.1440-1681.2009.05158.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1681.2009.05158.x","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,28]]}}}